|Bid||584.15 x 800|
|Ask||586.00 x 1200|
|Day's range||583.00 - 601.97|
|52-week range||309.20 - 629.97|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||105.23|
|Earnings date||06 Feb 2024|
|Forward dividend & yield||4.52 (0.77%)|
|Ex-dividend date||14 Nov 2023|
|1y target est||630.67|
Three Motley Fool contributors believe they've identified such exceptions. Here's why they think Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-brainer growth stocks to buy in December. David Jagielski (Eli Lilly): Eli Lilly is becoming a beast in the healthcare industry.
The investing icon helped Buffett build Berkshire Hathaway.
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.